<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014378</url>
  </required_header>
  <id_info>
    <org_study_id>00-061</org_study_id>
    <secondary_id>MSKCC-00061</secondary_id>
    <secondary_id>NCI-H01-0069</secondary_id>
    <nct_id>NCT00014378</nct_id>
  </id_info>
  <brief_title>Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study Of The Chinese Herb Huanglian (Coptis Chinesis) In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: The Chinese herb Huang Lian contains ingredients that may slow the growth of&#xD;
      cancer cells and may be an effective treatment for solid tumors.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of Huang Lian in treating patients who have&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of Huang Lian (Chinese herb) in patients with&#xD;
           advanced solid tumors.&#xD;
&#xD;
        -  Determine the optimal pharmacologic, molecular, and biologic parameters of this&#xD;
           treatment regimen in these patients.&#xD;
&#xD;
        -  Assess the preliminary therapeutic activity of this treatment regimen in this patient&#xD;
           population.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral Huang Lian (Chinese herb) 4 times daily. Treatment repeats every 21&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of Huang Lian until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-liming toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Chinese Herb Huanglian (Coptis chinesis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chinese Herb Huanglian (Coptis chinesis)</intervention_name>
    <description>Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).</description>
    <arm_group_label>Chinese Herb Huanglian (Coptis chinesis)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor refractory to standard therapy or for&#xD;
             which no standard therapy exists&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No CNS primary tumor or metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,500/mm^3&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of cardiac arrhythmias (including atrial fibrillation)&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina or myocardial infarction within the past 6 months&#xD;
&#xD;
          -  QTc interval no greater than 0.48 sec&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Potassium at least 3.5 mEq/L&#xD;
&#xD;
          -  Magnesium at least 1.4 mEq/L&#xD;
&#xD;
          -  No mental incapacity that would preclude informed consent&#xD;
&#xD;
          -  No serious or uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 2 weeks since prior herbal therapy for cancer and recovered&#xD;
&#xD;
          -  No concurrent class IA or III antiarrhythmic agents (e.g., quinidine, procainamide,&#xD;
             disopyramide, sotalol, amiodarone, ibutilide, almokalant, or dofetilide)&#xD;
&#xD;
          -  No concurrent tricyclic antidepressants (e.g., amitriptyline, doxepin, desipramine,&#xD;
             imipramine, or clomipramine)&#xD;
&#xD;
          -  No concurrent antiseizure medication (including dilantin and phenobarbital) for any&#xD;
             underlying seizure disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary K. Schwartz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

